Recursion Pharmaceuticals, Inc. (RXRX)

Recursion Pharmaceuticals, Inc. (RXRX) is a healthcare company (biotechnology) based in the United States. The share price is $2.70, down 7.06% on the day, which values the company at $1.68B. Price as of 17 Nov 2026, 20:35 UTC, from Yahoo Finance.

Key facts

Share price
$2.70−7.06% today
Market value
$1.68B
Funk Score
52/100
Against its own history
Well below its usual priceusual price $6.35
200-week average
$6.4258% below
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Recursion Pharmaceuticals, Inc. in more detail

RXRX trades at -3.3× next year's expected earnings, 24.7× sales. Measured against its own history, the price is 57% below what its usual multiples would imply ($6.35) — well below its usual price. It sits 58% below its 200-week average of $6.42.

Over the last five fiscal years Recursion Pharmaceuticals, Inc. has compounded revenue 79.7% a year. Its Funk Score is 52 out of 100 (financial strength 3.6, profitability 2.0, growth 10.0, value 5.0, each out of 10).

In its favour: Five straight years of revenue growth; More cash than debt. Worth checking: Altman Z in the distress zone; Beneish M-score flags the accounts.

2 of the superinvestors tracked here hold RXRX, including Cathie Wood (1.1% of the portfolio), Baillie Gifford team (0.1% of the portfolio).

Superinvestors holding RXRX

2 of the investors tracked here report a position in their latest 13F filing.

Recursion Pharmaceuticals, Inc. (RXRX): questions and answers

What is Recursion Pharmaceuticals, Inc.'s market cap?

Recursion Pharmaceuticals, Inc. is valued at $1.68B at a share price of $2.70.

Is RXRX overvalued or undervalued?

Against its own history, RXRX is well below its usual price: the price is 57% below the $6.35 implied by the median multiples it has traded at (price / sales, price / book). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

Is RXRX above its 200-week moving average?

No. RXRX is 58.0% below its 200-week average of $6.42. Long-term investors watch that line because strong companies rarely trade below it for long.

How fast is Recursion Pharmaceuticals, Inc. growing?

Over the last five fiscal years Recursion Pharmaceuticals, Inc.'s revenue grew 79.7% a year.

Does RXRX pay a dividend?

Recursion Pharmaceuticals, Inc. does not currently pay a regular dividend.

Which famous investors own RXRX?

In their latest quarterly filings, Cathie Wood (1.1% of the portfolio), Baillie Gifford team (0.1% of the portfolio) hold RXRX. These filings are published up to 45 days after each quarter ends, so positions may have changed since.

Cite this page

Funkfolio, “Recursion Pharmaceuticals, Inc. (RXRX) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/RXRX

Underlying data: Yahoo Finance; company filings with the SEC.